But in written testimony, AstraZeneca on November 1 proposed a mandatory requirement for pharmaceutical companies to submit all DTC advertising to FDA before the commercials air on television or appear in print.
The Pharmaceutical Research and Manufacturers of America (PhRMA) in guidelines issued in August called for companies to voluntarily submit all new DTC television advertisements to FDA before broadcasting the commercials. PhRMA's voluntary guidelines "are a solid first step," said Tony Zook, AstraZeneca's senior vice president of commercial operations. But, he said, his company views the industry lobbying group's principles as a "floor, not a ceiling." "If our collective goal is to ensure that accurate and responsible information is communicated to patients and health care providers, then manufacturers, patients, physicians, and policymakers ought to welcome such a review process," Zook said in a statement.
Fair and balanced? Ruth Day, professor of psychology and director of the Medical Cognition Laboratory at Duke University, said that research has clearly shown that there is an unfair balance in the presentation of benefits versus risks in DTC commercials, with the advertisements being weighted in favor of benefits.
A recent DTC study found that about 80% of consumers could correctly identify a medication's indication after viewing a prescription drug commercial, Day told regulators.
But, she said, when asked about a drug's risks, only about 20% of consumers could recall any information about the medication's potential adverse effects or contraindications.
Drug makers often use flashy, sparkling graphics to distract viewers and divide their attention when risk information is presented during an advertisement, Day said. "Risk information is there," she said. "It's physically present, but functionally absent." For instance, she explained, Schering-Plough uses a "charming" cartoon bee character in its commercials for its allergy product Nasonex.
But, Day exclaimed, "Watch his wings."
She demonstrated for regulators a simulation of how the bee's wings move quickly during the commercial's presentation of risk information. But, Day noted, when the narrator talks about the drug's benefits, the "wings are not moving. In fact, he doesn't have any wings at all."
A plotting of wing flaps per second during the presentation of benefits and risks found "clearly more [flaps] during the side effects," she declared.
Day's research found that risk information is placed in less favorable locations in drug advertisements than is benefit information.
"Sure it's great to have a positive treatment for benefits, but let's do that for risks as well so we have fair balance," she said.
Most DTC advertisements, Day maintained, use language understandable at a sixth-or seventh-grade level to discuss benefit information, while risk information is presented at the ninth-grade level.
"Is this fair balance?" she asked. "I think we would have to say 'No.'" Gary Stein, director of federal regulatory affairs for the American Society of Health-System Pharmacists (ASHP), told the 11-member FDA panel that risk information should be presented at a fourth-grade level.
"This will ensure that lay people understand the ads," he said.
The discussion of risks should not be presented with positive backdrop images, he contended. This so-called fields of flowers effect-images of people frolicking through fields of flowers, giving an impression that a drug will make a user just as happy as the carefree people shown in the commercialcreates an unrealistic expectation of a drug's efficacy and downplays the severity of potential adverse effects, said Alex Sugerman-Brozan, director of the Prescription Access Litigation project at Community Catalyst, a consumer advocate organization.
He argued that DTC advertisements promote medications as consumer goods rather than medical treatments.
His organization holds an annual event called the Bitter Pill Awards, which, he said, exposes drug companies' manipulation of consumers.
Inappropriate incentives. Sugerman-Brozan warned regulators about a "disturbing trend" of directing drug advertisements, particularly those for acne medications, toward children.
"Such advertisements use the same tactics of psychological manipulation that marketers have honed to a science to market junk food, toys, music, and movies to children," he contended.
Some of the advertisements are using "completely inappropriate" incentives aimed at teenagers, Sugerman-Brozan said.
For instance, he said, a promotion for Galderma's topical acne medication Differin offers teenagers a certain number of free Internet music downloads for every prescription filled.
A person gets 2 free music downloads for signing up for the online program, 7 for obtaining and filling a prescription for Differin, and 10 more music downloads for refilling a prescription-or, as the company calls it, "the 3 levels of cool." "So rock harder. And rock acne free," the advertisement states.
"Such linked promotions, if not already illegal, certainly should be," Sugerman-Brozan said.
ASHP's Stein said that other advertising incentives offered by drug companies, such as coupons and money-back guarantees, should also not be allowed "because they convey the idea that the medication always works and that there are no risks."
To ban or not to ban? Some critics at the November hearing told regulators that FDA should return to the agency's pre-1997 requirements or ban broadcast prescription drug commercials outright. But J. Patrick Kelly, president of Pfizer's U.S. Pharmaceuticals Division, argued that "DTC advertising helps patients work with health care providers to make more informed decisions about their health, which in turn, leads to needed diagnoses, appropriate treatment, and ultimately, better health outcomes for Americans and our nation."
Quoting results from a 2002 Harvard University-Harris Interactive study, Kelly said that DTC advertising has helped one in four patients receive a diagnosis for a previously unknown medical condition when they have asked about a DTC advertised product during a physician visit.
"More than 40% of these new diagnoses were for such high priority conditions as diabetes, high blood pressure, and asthma," he said. "This impact extends to other medical conditions that can have a major impact on consumer health and consumer quality of life. Often these are conditions such as overactive bladder and erectile dysfunction, which itself is often a surrogate marker for cardiovascular disease."
Free speech. Kelly charged that under the free speech clause of the First Amendment of the U.S. Constitution, "patients have the right to receive information in DTC advertising and our companies have a right to impart it."
Wally Snyder, president of the American Advertising Federation, agreed, stating that the Supreme Court "acknowledged [that] the free flow of advertising is as important as the free flow of news." "No one is going to strong-arm consumers about medicines or any other product," he said.
Critics concerned that DTC advertising is to blame for unnecessary use of prescription drugs are "misguided," he asserted.
A moratorium. Snyder urged FDA not to impose a moratorium on DTC promotions for prescription drugs.
"Ultimately, the issue is not about moratoriums on advertising, it is about regulation," he said. "If a drug is not ready, by all means, keep it off the market. But once approved, once the stringent requirements of clinical trials and other testing are done, and the drug [is] approved, please do not send a mixed message by banning advertising. Regulate the drug, but do not impede the flow of truthful information."
Bristol-Myers Squibb on June 13 announced it would refrain for a year after the launch of a new prescription medication before targeting advertising at consumers. Senate Majority Leader Bill Frist (RTennessee) on July 1 called for a two-year moratorium on DTC advertising for new drug products, stating that two years would give health care providers and patients time to learn more about medications "so we can be sure we are putting the needs, interests, and safety of our patients first."
A cure for health disparities? Several proponents of DTC advertising suggested at the hearing that the commercials help to relieve health disparities by motivating low-income patients to visit their physicians and seek treatment.
However, none of the presenters who purported the health disparities claim provided evidence for their statements.
